ASX Announcement 26 October 2026 Quarterly Activities Report for the Period Ended 30 September 2026 Key Performance Highlights • Record quarterly sales of $584k, representing the Company’s strongest sales quarter to date o Revenue up 774% from the corresponding quarter last year o A 176%...
Q1 FY27 Activities Report and Appendix 4C
Filed with ASX ·
6ix is reading this filing.
Earlier from Renerve
- Positive 12-Month Data for NervAlign Nerve Guide Matrix
- Positive FDA Feedback on NervAlign Nerve Guide Matrix
- ReNerve AGM Presentation
- ReNerve completes first cases in Hong Kong and Malaysia
- ReNerve and RMIT awarded $499k grant
